12 Month Price Forecast For CERS
Distance to CERS Price Forecasts
CERS Price Momentum
🤔 Considering Cerus (CERS)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: January 23, 2025 4:21 AM UTC
CERS Analyst Ratings & Price Targets
Based on our analysis of 5 Wall Street analysts, CERS has a consensus that is bullish. The median price target is $4.50, with forecasts ranging from $3.00 to $5.00. Currently, there are 4 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
With CERS currently trading at $1.81, the median price forecast suggests a 148.6% upside. The most optimistic forecast comes from at Craig-Hallum, projecting a 176.2% upside, while Mathew Blackman at Stifel provides the most conservative target, suggesting a 65.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CERS Analyst Consensus
CERS Price Target Range
Latest CERS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CERS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 17, 2024 | Stifel | Mathew Blackman | Buy | Maintains | $3.00 |
| May 3, 2024 | Cantor Fitzgerald | Ross Osborn | Overweight | Maintains | $4.00 |
| Apr 12, 2024 | Craig-Hallum | Buy | Initiates | $5.00 | |
| Mar 7, 2024 | Stephens & Co. | Jacob Johnson | Equal-Weight | Reiterates | $2.50 |
| Mar 6, 2024 | Cantor Fitzgerald | Ross Osborn | Overweight | Reiterates | $3.00 |
| Nov 8, 2023 | Cantor Fitzgerald | Ross Osborn | Overweight | Assumes | $3.00 |
| Jan 20, 2023 | BTIG | Mark Massaro | Neutral | Downgrade | $0.00 |
| May 27, 2020 | Stifel | Buy | Maintains | $8.00 | |
| Apr 16, 2020 | Stephens & Co. | Jacob Johnson | Overweight | Maintains | $6.50 |
| Feb 26, 2020 | BTIG | Buy | Initiates | $0.00 | |
| Feb 26, 2020 | BTIG Research | Buy | Initiates | $0.00 | |
| Nov 13, 2019 | BTIG Research | Buy | Upgrade | $0.00 | |
| Nov 13, 2019 | BTIG | Buy | Upgrade | $0.00 | |
| Aug 28, 2019 | Stifel | Buy | Initiates | $0.00 | |
| Apr 22, 2016 | BTIG | Buy | Maintains | $10.00 | |
| Apr 22, 2016 | BTIG Research | Buy | Maintains | $0.00 | |
| Dec 17, 2015 | Wedbush | Neutral | Downgrade | $0.00 | |
| Apr 24, 2015 | BTIG Research | Buy | Initiates | $0.00 | |
| Apr 24, 2015 | BTIG | Buy | Initiates | $0.00 | |
| Feb 27, 2015 | Cantor Fitzgerald | Buy | Maintains | $7.00 |
Stocks Similar to Cerus Corp
The following stocks are similar to Cerus based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Cerus Corp (CERS) Financial Data
Cerus Corp has a market capitalization of $343.57M with a P/E ratio of -8.6x. The company generates $176.23M in trailing twelve-month revenue with a -11.2% profit margin.
Revenue growth is +15.7% quarter-over-quarter, while maintaining an operating margin of -2.1% and return on equity of -38.3%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Cerus Corp (CERS) Company Overview
About Cerus Corp
Develops biomedical products for blood safety.
The company focuses on the development and commercialization of the INTERCEPT Blood System, which is designed to reduce blood-borne pathogens in donated blood components. It generates revenue by selling its proprietary blood safety systems for platelets, plasma, red blood cells, and cryoprecipitation through a direct sales force and distributors across various global markets.
Cerus Corporation was founded in 1991 and is based in Concord, California. Its innovative technology aims to enhance blood safety, which is crucial for medical transfusions, thereby addressing a significant need in the healthcare industry.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
625
CEO
Mr. William M. Greenman
Country
United States
IPO Year
1997
Website
www.cerus.comCerus Corp (CERS) Latest News & Analysis
Cerus Corporation (Nasdaq: CERS) projects 2024 product revenue at $180.3 million, surpassing its guidance of $177-$179 million, including $9.2 million from IFC revenue.
Cerus Corporation's preliminary revenue exceeds guidance, indicating strong performance and potential growth, which can enhance investor confidence and affect stock valuation.
Cerus Corporation (Nasdaq: CERS) will participate in the Stifel 2024 Healthcare Conference on November 18 and the Craig-Hallum Alpha Select Conference on November 19. A webcast will be available.
Cerus Corporation's participation in key investor conferences signals potential engagement with stakeholders, offering insights into its strategy and performance that may influence stock valuation.
Cerus Corporation (NASDAQ:CERS) will hold its Q3 2024 Earnings Conference Call on October 30, 2024, at 4:30 PM ET, featuring key company executives and financial analysts.
Cerus Corporation's Q3 earnings call could reveal key financial metrics and strategic insights, influencing stock performance and investor sentiment.
Cerus Corporation reported Q3 2024 revenue of $46.0M, up 16% year-over-year, and $129.5M for nine months, an 18% increase compared to 2023. Product revenue drove this growth.
Cerus Corporation's revenue growth of 16% in Q3 and 18% year-to-date signals strong market demand and potential for continued financial health, impacting stock valuations and investor confidence.
Cerus (CERS) Reports Q3 Loss, Tops Revenue Estimates
2 months agoCerus (CERS) reported a quarterly loss of $0.02 per share, better than the expected loss of $0.03, and improved from a loss of $0.03 per share a year ago.
Cerus's smaller-than-expected quarterly loss signals potential operational improvements, which may boost investor confidence and impact stock performance positively.
Cerus Corporation (Nasdaq: CERS) will release its Q3 2024 financial results on October 30, 2024, after market close, followed by a conference call at 4:30 PM ET.
Cerus Corporation's upcoming financial results and investor call could influence stock performance, offering insights into the company's health and future prospects.
Frequently Asked Questions About CERS Stock
What is Cerus Corp's (CERS) stock forecast for 2025?
Based on our analysis of 5 Wall Street analysts, Cerus Corp (CERS) has a median price target of $4.50. The highest price target is $5.00 and the lowest is $3.00.
Is CERS stock a good investment in 2025?
According to current analyst ratings, CERS has 4 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.81. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for CERS stock?
Wall Street analysts predict CERS stock could reach $4.50 in the next 12 months. This represents a 148.6% increase from the current price of $1.81. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Cerus Corp's business model?
The company focuses on the development and commercialization of the INTERCEPT Blood System, which is designed to reduce blood-borne pathogens in donated blood components. It generates revenue by selling its proprietary blood safety systems for platelets, plasma, red blood cells, and cryoprecipitation through a direct sales force and distributors across various global markets.
What is the highest forecasted price for CERS Cerus Corp?
Price targets from Wall Street analysts for CERS are not currently available. The stock is trading at $1.81.
What is the lowest forecasted price for CERS Cerus Corp?
The lowest price target for CERS is $3.00 from Mathew Blackman at Stifel, which represents a 65.7% increase from the current price of $1.81.
What is the overall CERS consensus from analysts for Cerus Corp?
The overall analyst consensus for CERS is bullish. Out of 5 Wall Street analysts, 4 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $4.50.
How accurate are CERS stock price projections?
Stock price projections, including those for Cerus Corp, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
